Three studies presented at the American Glaucoma Society meeting demonstrated the potential benefit of NCX 470 in patients with glaucoma.
NCX 470 (Nicox) is a nitric oxide-donating bimatoprost eye drop designed to lower IOP in patients with glaucoma. Sanjay G. Asrani, MD, presented data from the phase 3 DENALI trial that compared NCX 470 with latanoprost 0.005% in 696 patients with glaucoma or ocular hypertension.
As Healio previously reported, NCX 470 achieved noninferiority in lowering IOP compared with latanoprost. Asrani said in his presentation that NCX 470 demonstrated greater IOP